receptor agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-06 and is reviewed periodically as new material appears.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
IgA vasculitis (Henoch-Schönlein purpura) Acute hemorrhagic edema of infancy Urticarial vasculitis Cryoglobulinemic vasculitis Erythema elevatum diutinum Granuloma faciale ANCA-associated vasculitis Arthropod bites Platelet dysfunction or deficiency Cholesterol emboli Septic emboli Livedoid vasculopathy
Professor Juan J. Calvete is a researcher in venomics at the biomedical institute in Valencia and has extensively explained the process involved in untangling and analysing venom (Once in 2007 and recently in 2017.) These involve the following steps: (1) Venom collection, (2) Separation and quantification, (3) Identification and (4) Representation of components found.
== Essays == "The Philosophy of Dress" First published in The New-York Tribune (1885), published for the first time in book form in Oscar Wilde On Dress (2013). "The Decay of Lying" First published in Nineteenth Century (1889), republished in Intentions (1891). "Pen, Pencil and Poison" First published in the Fortnightly Review (1889), republished in Intentions (1891). "The Soul of Man under Socialism" First published in the Fortnightly Review (1891), republished in The Soul of Man (1895), privately printed. ("The Soul of Man Under Socialism" on Wikisource) Intentions (1891) Wilde revised his dialogues on aesthetic subjects for publication in this volume, which comprises: "The Critic as Artist" "The Decay of Lying" "The Truth of Masks" "Phrases and Philosophies for the Use of the Young" first published in the Oxford student magazine The Chameleon, December 1894) ("Phrases and Philosophies for the Use of the Young" on Wikisource) "A Few Maxims For The Instruction Of The Over-Educated" First published, anonymously, in the 1894 November 17 issue of Saturday Review.
=== Analysers === The Microtox Model 500 is a laboratory-based photometer that measures acute toxicity. This analyser is a temperature-controlled, self-calibrating biosensor measuring system that uses the bioluminescence of Allivibrio fischeri to determine the toxicity of contaminated water, or elutriates of contaminated soils and sediments. Microtox Continuous Toxicity Monitor (CTM) is a site-specific Microtox analyser that continuously measures the toxicity of a water source and provides results instantly. This fully automatic analyser has a broad detection range that can identify several thousand contaminants simultaneously whether or not there is knowledge of the source of contamination. This device has the ability to run continuously for up to 4 weeks, and is easy to operate and maintain. The DeltaTox II is a portable instrument that can be used to conduct acute toxicity and adenosine triphosphate (ATP) testing. Also known as the portable version of the Microtox Model 500, this device provides simple testing, uses small sample sizes, and is a cost-effective approach to analyzing water samples. This sensitive and rapid testing analyser has the ability to detect microbial contamination, as well as more than 2,700 different chemicals.
Numerous protesters asked for a civilian government. On Saturday 13 April 2019, al-Burhan announced that a civilian government would soon be established. Al-Burhan promised that the transitional period would take a maximum of two years. Negotiations started to take place with the opposition leaders to achieve this.
Sources: en.wikipedia.org
Protandim is a herbal dietary supplement marketed with unsupported claims that it can treat a number of medical conditions. The product is a patented mix of five herbal ingredients and sold by LifeVantage Corporation (formerly LifeLine Therapeutics, Lifeline Nutraceuticals, and Yaak River Resources, Inc), a Utah-based multi-level marketing company. The manufacturers of Protandim make no claims that it can prevent or cure any medical conditions. In 2017, LifeVantage was issued a warning letter by the U.S. Food and Drug Administration (FDA) regarding illegal advertising claims on the company's websites suggesting that Protandim can help to cure various ailments, including cancer and diabetes.
=== Prostate conditions === Spironolactone has been studied at a high dosage in the treatment of benign prostatic hyperplasia (BPH; enlarged prostate). It was found to be better than placebo in terms of symptom relief following three months of treatment. However, this was not maintained after six months of treatment, by which point the improvements had largely disappeared. Moreover, no difference was observed between spironolactone and placebo with regard to volume of residual urine or prostate size. Gynecomastia was observed in about 5% of people. On the basis of these results, it has been said that spironolactone has no place in the treatment of BPH. Spironolactone has been studied and used limitedly in the treatment of prostate cancer.
== Description line == The description line (defline) or header/identifier line, which begins with ">", gives a name and/or a unique identifier for the sequence, and may also contain additional information. In a deprecated practice, the header line sometimes contained more than one header, separated by a ^A (Control-A) character. In the original Pearson FASTA format, one or more comments, distinguished by a semi-colon at the beginning of the line, may occur after the header. Some databases and bioinformatics applications do not recognize these comments and follow the NCBI FASTA specification. An example of a multiple sequence FASTA file follows:
The southern districts of Le Havre are mainly used for industrial and port activities. There are buildings in brick from the 19th century, large developments (Chicago, Les Neiges), worker estates, SMEs, warehouses, dock and port facilities, and transport infrastructure. The southern districts have for some years experienced profound change due to European funding. It is revitalizing areas neglected by industrial and port activities by developing tertiary activities. Thus, the docks have been completely transformed into sports and entertainment complexes (Dock Océane), a mall (Docks Vauban), and an exhibition hall (Docks Café). Les Bains Des Docks was designed by the architect Jean Nouvel. At the end of 2012 students from Sciences Po's Europe-Asia undergraduate college campus and from INSA integrated new buildings next to the ISEL (Higher Institute of logistics studies) and the future ENSM (Ecole Nationale Supérieure Maritime). The new medical axis around the new Clinic des Ormeaux was built in the neighbourhoods where many homes are planned with the aim of promoting social mix. The City of the Sea and of Sustainable Development (Odyssey 21) will be organized around a metal tower one hundred metres high designed by Jean Nouvel: the project was suspended in 2007 but the work should finally begin in 2013. The municipality has to attract some 300,000 visitors per year.
== Limitations == Despite its aforementioned advantages as a specialized tool, the B1H system does have some drawbacks. First, the B1H selection system is limited in its capacity to determine the binding specificities of transcription factors with lengthy binding sites. This arises from the fact that the number of randomized “prey” clones required to represent all possible target sequences increases exponentially with the number of nucleotides in that target sequence. Second, some eukaryotic factors may not express or fold efficiently in the bacterial system, attributed to differing regulatory networks and transcriptional machinery. Hence when working with DNA-binding proteins of eukaryotic origin, a yeast-based hybrid system may be beneficial. Third, the B1H system may not be ideally suited for transcription factors that recognize binding sites with low affinity. The logic here is that competition created by binding sites elsewhere in the bacterial genome may limit the signal that can be realized from a single binding site that is present upstream of the reporter.
Sources: en.wikipedia.org
During orgasm, rhythmic muscle contractions occur in the outer third of the vagina, as well as the uterus and anus. Contractions become less intense and more randomly spaced as the orgasm continues. The number of contractions that accompany an orgasm vary depending on its intensity. An orgasm may be accompanied by female ejaculation, causing liquid from the Skene's glands to be expelled through the urethra. The pooled blood begins to dissipate, although at a much slower rate if an orgasm has not occurred. The vagina and its opening return to their normal relaxed state, and the rest of the vulva returns to its normal size, position and color.
In May 1991, the PDRE (1987-1991) was overthrown by forces consisting of the TPLF and the TPLF-controlled EPRDF with the promise that a recognition of human rights, democracy, the liberalization of the economic sector, and political rehabilitation were soon to follow. The PDRE, the country's newest civilian regime, was actually dominated by leaders of the preceding Derg (1974-1987) a military junta led by Mengistu Haile Mariam that seized power by overthrowing the long-ruling Emperor Haile Selassie I in 1974. The Derg (meaning "committee" or "council") and its leaders were known for dramatically restructuring the country's political and economic institutions, often through the use of suppression and fear, while transforming the central government's role in domestic affairs. Programs such as the extensive villagization schemes carried out in various parts of the country further served as a testament to the regime's commitment to radical reform measures. Once in power, the leaders of the PDRE continued pursuing their aims as former Derg leaders, such as by resuming forced resettlement programs that were deemed nonviable by many and were ultimately met with a considerable amount of international criticism. Scholars have noted that the fall of the PDRE was largely made possible by the loss of both financial and military support from the dwindling Soviet Union, which had previously backed the Derg following their seizure of power in 1974.
== Examples == Some examples of conjugated proteins are lipoproteins, glycoproteins, nucleoproteins, phosphoproteins, hemoproteins, flavoproteins, metalloproteins, phytochromes, cytochromes, opsins, and chromoproteins.
Due to the legal and military tensions, the Hungarian parliament did not grant Franz Joseph that favour. Francis Joseph was, in the strict constitutional sense, a textbook usurper in Hungary: under the Pragmatic Sanction of 1723 (Arts. I–III) and the established Hungarian constitutional law governing succession and coronation, the throne was not vacant while the crowned King Ferdinand V was still alive, and Ferdinand’s unilateral abdication could not by itself make Francis Joseph King of Hungary; without the consent of the Hungarian Diet, the constitutional oath, and coronation with the Holy Crown, Francis Joseph had no lawful authority to exercise the Hungarian royal power—his seizure of that power thus constituting a clear case of usurpation. In short: Francis Joseph was regarded by Hungarians as a usurper and a rebel against the ancient constitution and the established order.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.